<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: rgbp.xfr; Date: 2021%2D08%2D04T07:29:12Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://regenbiopharma.com/role/DocumentAndEntityInformation" xlink:href="rgbp-20200930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConsolidatedBalanceSheet" xlink:href="rgbp-20200930.xsd#ConsolidatedBalanceSheet" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConsolidatedBalanceSheetParenthetical" xlink:href="rgbp-20200930.xsd#ConsolidatedBalanceSheetParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConsolidatedStatementOfOperations" xlink:href="rgbp-20200930.xsd#ConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" xlink:href="rgbp-20200930.xsd#ConsolidatedStatementOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/StatementOfShareholdersDeficit" xlink:href="rgbp-20200930.xsd#StatementOfShareholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="rgbp-20200930.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/RecentAccountingPronouncements" xlink:href="rgbp-20200930.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/GoingConcern" xlink:href="rgbp-20200930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/NotesPayable" xlink:href="rgbp-20200930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConvertibleNotesPayable" xlink:href="rgbp-20200930.xsd#ConvertibleNotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/IncomeTaxes" xlink:href="rgbp-20200930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/RelatedPartyTransactions" xlink:href="rgbp-20200930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/AccountsReceivableRelatedParty" xlink:href="rgbp-20200930.xsd#AccountsReceivableRelatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/CommitmentsAndContingencies" xlink:href="rgbp-20200930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/StockholdersEquity" xlink:href="rgbp-20200930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/InvestmentSecurities" xlink:href="rgbp-20200930.xsd#InvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/StockTransactions" xlink:href="rgbp-20200930.xsd#StockTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/SubsequentEvents" xlink:href="rgbp-20200930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rgbp-20200930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="rgbp-20200930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/NotesPayableTables" xlink:href="rgbp-20200930.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/IncomeTaxesTables" xlink:href="rgbp-20200930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/InvestmentSecuritiesTables" xlink:href="rgbp-20200930.xsd#InvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="rgbp-20200930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="rgbp-20200930.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/GoingConcernDetailsNarrative" xlink:href="rgbp-20200930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/NotesPayableRelatedPartyDetails" xlink:href="rgbp-20200930.xsd#NotesPayableRelatedPartyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/NotesPayableRelatedPartyDetailsNarrative" xlink:href="rgbp-20200930.xsd#NotesPayableRelatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="rgbp-20200930.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/IncomeTaxesDetails" xlink:href="rgbp-20200930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="rgbp-20200930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="rgbp-20200930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="rgbp-20200930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/InvestmentSecuritiesDetails" xlink:href="rgbp-20200930.xsd#InvestmentSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/InvestmentSecuritiesDetails1" xlink:href="rgbp-20200930.xsd#InvestmentSecuritiesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" xlink:href="rgbp-20200930.xsd#InvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" xlink:href="rgbp-20200930.xsd#StockTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="rgbp-20200930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConsolidatedBalanceSheet" xlink:title="00000002 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaapAvailableForSaleSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapAvailableForSaleSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankOverdrafts" xlink:label="loc_us-gaapBankOverdrafts" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapBankOverdrafts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansPayable" xlink:label="loc_us-gaapNotesAndLoansPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesAndLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_AccruedRent" xlink:label="loc_RGBPAccruedRent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RGBPAccruedRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_OtherAccruedExpenses" xlink:label="loc_RGBPOtherAccruedExpenses" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RGBPOtherAccruedExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_DueToInvestor" xlink:label="loc_RGBPDueToInvestor" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RGBPDueToInvestor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount" xlink:label="loc_RGBPConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_RGBPConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNonCurrent" xlink:label="loc_RGBPConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNonCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_RGBPConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAdditionalCapital" xlink:label="loc_us-gaapOtherAdditionalCapital" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapOtherAdditionalCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConsolidatedBalanceSheetParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCostsAndExpenses" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_RefundsOfAmountsPreviouslyPaid" xlink:label="loc_RGBPRefundsOfAmountsPreviouslyPaid" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_RGBPRefundsOfAmountsPreviouslyPaid" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_BadDebtExpense" xlink:label="loc_RGBPBadDebtExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_RGBPBadDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_InterestExpenseAttributableToAmortizationOfDiscount" xlink:label="loc_RGBPInterestExpenseAttributableToAmortizationOfDiscount" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_RGBPInterestExpenseAttributableToAmortizationOfDiscount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_GainLossOnEarlyExtinguishmentConvertibleDebt" xlink:label="loc_RGBPGainLossOnEarlyExtinguishmentConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_RGBPGainLossOnEarlyExtinguishmentConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_UnrealizedGainLossOnInvestmentSecuritiesRelatedParty" xlink:label="loc_RGBPUnrealizedGainLossOnInvestmentSecuritiesRelatedParty" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_RGBPUnrealizedGainLossOnInvestmentSecuritiesRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNoncashIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConsolidatedStatementOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_PreferredStockIssued2" xlink:label="loc_RGBPPreferredStockIssued2" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPPreferredStockIssued2" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_SubsidiaryStockIssuedToConsultants" xlink:label="loc_RGBPSubsidiaryStockIssuedToConsultants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPSubsidiaryStockIssuedToConsultants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_SubsidiaryStockIssuedAsCompensation" xlink:label="loc_RGBPSubsidiaryStockIssuedAsCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPSubsidiaryStockIssuedAsCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_CommonStockIssuedForExpenses" xlink:label="loc_RGBPCommonStockIssuedForExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPCommonStockIssuedForExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_GainLossOnSaleOfInvestmentSecurities" xlink:label="loc_RGBPGainLossOnSaleOfInvestmentSecurities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPGainLossOnSaleOfInvestmentSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInNotesReceivables" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInNotesReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_IncreasedecreaseInBankOverdraft" xlink:label="loc_RGBPIncreasedecreaseInBankOverdraft" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPIncreasedecreaseInBankOverdraft" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_IncreasedecreaseInContributedCapital" xlink:label="loc_RGBPIncreasedecreaseInContributedCapital" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_RGBPIncreasedecreaseInContributedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_IncreasedecreaseInSaleOfInvestmentSecurities" xlink:label="loc_RGBPIncreasedecreaseInSaleOfInvestmentSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_RGBPIncreasedecreaseInSaleOfInvestmentSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_CommonStockIssuedForCash" xlink:label="loc_RGBPCommonStockIssuedForCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RGBPCommonStockIssuedForCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_PreferredStockIssuedForCash" xlink:label="loc_RGBPPreferredStockIssuedForCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RGBPPreferredStockIssuedForCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="rgbp-20200930.xsd#RGBP_IncreaseDecreaseInConvertibleNotesPayableCurrent" xlink:label="loc_RGBPIncreaseDecreaseInConvertibleNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_RGBPIncreaseDecreaseInConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/StatementOfShareholdersDeficit" xlink:title="00000006 - Statement - Consolidated Statement of Shareholder&#8217;s Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - Organization and Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/GoingConcern" xlink:title="00000009 - Disclosure - Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/NotesPayable" xlink:title="00000010 - Disclosure - Notes Payable, Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConvertibleNotesPayable" xlink:title="00000011 - Disclosure - Convertible Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/AccountsReceivableRelatedParty" xlink:title="00000014 - Disclosure - Accounts Receivable, Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - Stockholders Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/InvestmentSecurities" xlink:title="00000017 - Disclosure - Investment Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/StockTransactions" xlink:title="00000018 - Disclosure - Stock Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/SubsequentEvents" xlink:title="00000019 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/NotesPayableTables" xlink:title="00000022 - Disclosure - Notes Payable, Related Party (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/InvestmentSecuritiesTables" xlink:title="00000024 - Disclosure - Investment Securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/GoingConcernDetailsNarrative" xlink:title="00000027 - Disclosure - Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/NotesPayableRelatedPartyDetails" xlink:title="00000028 - Disclosure - Notes Payable, Related Party (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/NotesPayableRelatedPartyDetailsNarrative" xlink:title="00000029 - Disclosure - Notes Payable, Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000030 - Disclosure - Convertible Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/IncomeTaxesDetails" xlink:title="00000031 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000032 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000034 - Disclosure - Stockholders Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/InvestmentSecuritiesDetails" xlink:title="00000035 - Disclosure - Investment Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/InvestmentSecuritiesDetails1" xlink:title="00000036 - Disclosure - Investment Securities (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/InvestmentSecuritiesDetailsNarrative" xlink:title="00000037 - Disclosure - Investment Securities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/StockTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - Stock Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://regenbiopharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000039 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>


